Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

BACKGROUND: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeimy, Samira, Basharat, Pari, Lovegrove, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756/
https://www.ncbi.nlm.nih.gov/pubmed/30675173
http://dx.doi.org/10.1186/s13223-019-0319-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756/
https://www.ncbi.nlm.nih.gov/pubmed/30675173
http://dx.doi.org/10.1186/s13223-019-0319-4

Ejemplares similares